This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 1433 studies, archived under the term: ""

Click here to filter this large number of results.

Influence of adherence to a systematic care program for caregivers of dementia patients

Objective: To evaluate the influence of adherence to the Systematic Care Program for Dementia (SCPD) intervention protocol on patient and caregiver outcomes.; Design: Data were drawn from the SCPD study-a single-blind, multicenter, cluster-randomized, controlled trial. Multivariate regression analyses were used to assess the influence of adherence on patient and caregiver outcomes.; Setting: Six community mental health […]

CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans

Reports on the value of cerebrospinal fluid (CSF) α-synuclein as a biomarker for dementia with Lewy bodies and Parkinson disease are contradicting. This may be explained by fluctuating CSF α-synuclein concentrations over time. Such fluctuations have been suggested for CSF amyloid β concentrations. Furthermore, a physiological relationship between α-synuclein and amyloid β has been suggested […]

Cognitive Stimulation Therapy (CST): effects on different areas of cognitive function for people with dementia

Background: There is good evidence indicating that group Cognitive Stimulation Therapy (CST) leads to generalised cognitive benefits for people with dementia. However, little is known about whether some aspects of cognition might change more than others and why.; Methods: Cognitive Stimulation Therapy, a 14-session group treatment, has been evaluated in a multi-centre, single-blind, randomised controlled […]

Rivastigmine patch ameliorates depression in mild AD: Preliminary evidence from a 6-month open-label observational study

Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild Alzheimer’s Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n = 50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE […]

Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort

Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive or no drugs.; Design: Four-year prospective multicenter cohort study with a biannual assessment.; Setting: Memory clinics from 16 university hospitals in France.; Participants: Community-dwelling older adults with […]

Cognitive subdomain responses to galantamine in Alzheimer’s disease

We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of […]

Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep

Many patients with Alzheimer’s disease experience sleep disturbances, and donepezil is usually prescribed for night-time administration. However, increased acetylcholine is associated with cortical arousal. We evaluated whether subjective sleep quality differed according to the timing of medication administration. Ninety-two patients with mild to moderate Alzheimer’s disease who had taken donepezil at night (n=54) or galantamine […]

Reliability and validity of the Norwegian version of the Brief Agitation Rating Scale (BARS) in dementia

Objective: To examine the test-retest reliability and validity of the Norwegian Brief Agitation Rating Scale (BARS), a short form of the Cohen-Mansfield Agitation Inventory (CMAI) assessing the frequency of agitation in dementia.; Methods: We investigated the internal consistency, test-retest reliability and the validity of BARS. In the validity study, we compared the BARS scores with […]

Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease

Previous studies with functional magnetic resonance imaging (fMRI) demonstrated a differential brain activity and connectivity after treatment with donepezil in Alzheimer’s disease (AD) when compared to healthy elders. Importantly however, there are no available studies where the placebo or control group included comparable AD patients relative to the treated groups. Fifteen patients recently diagnosed of […]

Cost analysis of early psychosocial intervention in Alzheimer’s disease

Background/aim: To investigate the impact of early psychosocial intervention aimed at patients with Alzheimer’s disease (AD) and their caregivers on resource use and costs from a societal perspective.; Methods: Dyads of patients and their primary caregiver were randomised to intervention (n = 163) or control (n = 167) and followed for 3 years. Health care […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: